Focalin XR FDA Approval History
FDA Approved: Yes (First approved May 26, 2005)
Brand name: Focalin XR
Generic name: dexmethylphenidate
Dosage form: Extended-Release Capsules
Company: Novartis Pharmaceuticals Corporation
Treatment for: ADHD
Focalin XR (dexmethylphenidate) is a once-daily extended-release form of Focalin indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, adolescents and children.
Development timeline for Focalin XR
| Date | Article |
|---|---|
| Nov 12, 2008 | Approval FDA Approves 30-Minute Onset of Action for Focalin XR |
| May 26, 2005 | Approval Focalin XR Novartis Pharmaceuticals Corporation - Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
